Sii experts supported one of the world’s largest biotechnology companies by building a solution that replaces a business-critical pharmacovigilance system. By introducing test automation with Tricentis Tosca, Sii was able to reduce the company’s costs and time spent on testing the new solution.
Sii’s biotech client is running an innovation program that aims to build a solution based on artificial intelligence. The program will enable a highly automated, end-to-end process for the identification, characterization, and reporting for drug adverse events by applying cognitive computing and advanced analytics.
This complex undertaking includes three major applications delivered by external vendors, as well as custom developed platforms for the purpose of integration, reconciliation, and aggregate monitoring. The program uses a variety of technologies like Snowflake, PostgreSQL, API, ETL, MuleSoft, Spotfire, Tableau, AI, and LP. Applications within the program scope deal with patient personal data, and directly impact customer core business continuity as well as regulations established by the relevant health authorities.